“…With bortezomib, adverse events ranging from skin rash to thrombocytopenia, leukopenia, and neutropenia are reported [5]. Bortezomib-induced skin issues, including cutaneous vasculitis, are common but poorly understood [6,7]. In bortezomib clinical trials, vasculitis and rashes are reported in 8-18% of patients.…”